Stem Cells: Steady Momentum Toward Funding

Federal funding for research involving human embryonic stem cells (ESCs) is moving closer to reality as the Bush administration rushes to finalize a public registry of approved cell line providers. In late August, the National Institutes of Health announced 10 organizations that it said had developed 64 stem cell lines that meet all the criteria for federal funding (see table). Nevertheless, some licensing and patent issues need to be resolved and new and potentially complicating questions are e

Written byTed Agres
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

During the three weeks after President George W. Bush announced limited federal funding for human ESC research Aug. 9, NIH officials held virtually nonstop discussions, in person and by telephone, with the 10 potential stem cell line suppliers. To be eligible for federal funding, Bush said ESC lines had to be derived with informed consent of donors, from excess embryos created solely for reproductive purposes, without any financial inducements to the donors, and had been created prior to the time of his announcement.

Many scientists have been skeptical over the quality of the cells, especially following reports that up to half of the 64 lines may not be developed sufficiently for research. During a Sept. 5 Senate hearing, Health and Human Services Secretary Tommy Thompson acknowledged that some of these lines "are in the earliest stages of development," but he stressed their usefulness can only be determined through actual research. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies